[go: up one dir, main page]

NO20091141L - Pyrido (2,3-D) pyrimidinone compounds and their use as P13 inhibitors - Google Patents

Pyrido (2,3-D) pyrimidinone compounds and their use as P13 inhibitors

Info

Publication number
NO20091141L
NO20091141L NO20091141A NO20091141A NO20091141L NO 20091141 L NO20091141 L NO 20091141L NO 20091141 A NO20091141 A NO 20091141A NO 20091141 A NO20091141 A NO 20091141A NO 20091141 L NO20091141 L NO 20091141L
Authority
NO
Norway
Prior art keywords
inhibitors
pyrido
pyrimidinone compounds
compounds
pyrimidinone
Prior art date
Application number
NO20091141A
Other languages
Norwegian (no)
Other versions
NO342357B1 (en
Inventor
Mitchell David Nambu
Hengmiao Cheng
Mary Catherine Johnson
Jacqui Elizabet Hoffman
Robert Steven Kania
Phuong Thi Quy Le
Mason Alan Pairish
Dilip Bhumralkar
Klaus Ruprecht Dress
Michael Bruno Plewe
Khanh Tuan Tran
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of NO20091141L publication Critical patent/NO20091141L/en
Publication of NO342357B1 publication Critical patent/NO342357B1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Pyridine Compounds (AREA)

Abstract

Foreliggende oppfinnelse angår nye 4-metylpyridopyrimidinonforbindelser med formel (1), og salter derav, deres syntese og deres anvendelse som inhibitorer av fosfoinositid 3-kinase alfa (PI3-Koc).The present invention relates to novel 4-methylpyridopyrimidinone compounds of formula (1), and salts thereof, their synthesis and their use as inhibitors of phosphoinositide 3-kinase alpha (PI3-Koc).

NO20091141A 2006-09-15 2009-03-18 Pyrido (2,3-d) -pyrimidinone compounds, pharmaceutical composition and their use as PI3 inhibitors NO342357B1 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US84506506P 2006-09-15 2006-09-15
US94785207P 2007-07-03 2007-07-03
US95262807P 2007-07-30 2007-07-30
PCT/IB2007/002578 WO2008032162A1 (en) 2006-09-15 2007-09-03 Pyrido (2, 3-d) pyrimidin0ne compounds and their use as pi3 inhibitors

Publications (2)

Publication Number Publication Date
NO20091141L true NO20091141L (en) 2009-03-31
NO342357B1 NO342357B1 (en) 2018-05-14

Family

ID=38859750

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20091141A NO342357B1 (en) 2006-09-15 2009-03-18 Pyrido (2,3-d) -pyrimidinone compounds, pharmaceutical composition and their use as PI3 inhibitors

Country Status (41)

Country Link
US (3) US7696213B2 (en)
EP (1) EP2074122B9 (en)
JP (1) JP4718637B2 (en)
KR (1) KR101099926B1 (en)
CN (1) CN101573358B (en)
AP (1) AP2710A (en)
AR (1) AR062785A1 (en)
AT (1) ATE514695T1 (en)
AU (1) AU2007297212B8 (en)
BR (1) BRPI0716749B8 (en)
CA (1) CA2663401C (en)
CL (1) CL2007002682A1 (en)
CR (1) CR10662A (en)
CU (1) CU23783B7 (en)
CY (1) CY1111911T1 (en)
DK (1) DK2074122T5 (en)
DO (1) DOP2009000039A (en)
EA (1) EA016388B1 (en)
ES (1) ES2366489T3 (en)
GE (1) GEP20115306B (en)
GT (1) GT200700077A (en)
HN (1) HN2007000267A (en)
HR (1) HRP20110621T2 (en)
IL (1) IL197243A (en)
MA (1) MA30709B1 (en)
ME (1) MEP8009A (en)
MX (1) MX2009002927A (en)
MY (1) MY146420A (en)
NI (1) NI200900032A (en)
NO (1) NO342357B1 (en)
NZ (1) NZ575167A (en)
PE (1) PE20080670A1 (en)
PL (1) PL2074122T3 (en)
PT (1) PT2074122E (en)
RS (2) RS20090104A (en)
SI (1) SI2074122T1 (en)
TN (1) TN2009000085A1 (en)
TW (1) TWI334353B (en)
UY (1) UY30588A1 (en)
WO (1) WO2008032162A1 (en)
ZA (1) ZA200901477B (en)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0716749B8 (en) 2006-09-15 2021-05-25 Pfizer Prod Inc pyrido(2,3-d) pyrimidinone compounds, their use as pi3 inhibitors and pharmaceutical composition comprising them
WO2008124161A1 (en) * 2007-04-10 2008-10-16 Exelixis, Inc. Methods of treating cancer using pyridopyrimidinone inhibitors of pi3k alpha
AU2008239596B2 (en) * 2007-04-11 2013-08-15 Exelixis, Inc. Pyrido [2,3-D] pyrimidin-7-one compounds as inhibitors of PI3K-alpha for the treatment of cancer
CA2729914A1 (en) * 2008-07-11 2010-01-14 Novartis Ag Combination of (a) a phosphoinositide 3-kinase inhibitor and (b) a modulator of ras/raf/mek pathway
WO2010022121A1 (en) 2008-08-20 2010-02-25 Schering Corporation Substituted pyridine and pyrimidine derivatives and their use in treating viral infections
US8470834B2 (en) 2008-08-20 2013-06-25 Merck Sharp & Dohme Corp. AZO-substituted pyridine and pyrimidine derivatives and their use in treating viral infections
CA2734489C (en) 2008-08-20 2016-11-08 Southern Research Institute Ethenyl-substituted pyridine and pyrimidine derivatives and their use in treating viral infections
WO2010022125A1 (en) 2008-08-20 2010-02-25 Schering Corporation Ethynyl-substituted pyridine and pyrimidine derivatives and their use in treating viral infections
UY32153A (en) * 2008-09-30 2011-04-29 Exelixis Inc PY13KA (ALFA) AND MTOR PYRIDOMIDINONE INHIBITORS
US9526648B2 (en) 2010-06-13 2016-12-27 Synerz Medical, Inc. Intragastric device for treating obesity
US8628554B2 (en) 2010-06-13 2014-01-14 Virender K. Sharma Intragastric device for treating obesity
US10420665B2 (en) 2010-06-13 2019-09-24 W. L. Gore & Associates, Inc. Intragastric device for treating obesity
US10010439B2 (en) 2010-06-13 2018-07-03 Synerz Medical, Inc. Intragastric device for treating obesity
BR112013014914B8 (en) 2010-12-16 2020-08-04 Hoffmann La Roche compound, pharmaceutical composition and use of a compound
US8664230B2 (en) * 2011-03-17 2014-03-04 The Asan Foundation Pyridopyrimidine derivatives and use thereof
TW201306842A (en) * 2011-06-15 2013-02-16 Exelixis Inc Combination therapies for treating hematologic malignancies using pyridopyrimidinone inhibitors of PI3K/MTOR with bendamustine and/or rituximab
KR20140072028A (en) 2011-08-31 2014-06-12 노파르티스 아게 Synergistic combinations of pi3k- and mek-inhibitors
CN104829609B (en) * 2014-02-11 2016-08-03 北大方正集团有限公司 Substituted Pyridopyrimidine compound and its preparation method and application
CN105294682B (en) 2014-07-26 2017-07-07 广东东阳光药业有限公司 Compound of CDK type small molecular inhibitors and application thereof
CN105330699B (en) * 2014-08-13 2018-12-04 山东汇睿迪生物技术有限公司 A kind of phosphorous pyrido [2,3-d] pyrimidin-7-ones class compound or its pharmaceutically acceptable salt, pharmaceutical composition and its application
KR20170058432A (en) 2014-10-10 2017-05-26 화이자 인코포레이티드 Synergistic auristatin combinations
PE20180395A1 (en) 2015-06-04 2018-02-28 Pfizer SOLID DOSAGE FORMS OF PALBOCICLIB
US10779980B2 (en) 2016-04-27 2020-09-22 Synerz Medical, Inc. Intragastric device for treating obesity
EP4086250B1 (en) 2016-07-06 2024-12-11 The Regents Of The University Of Michigan Multifunctional inhibitors of mek/pi3k and mtor/mek/pi3k biological pathways and therapeutic methods using the same
AU2017311645B2 (en) * 2016-08-15 2021-05-27 Pfizer Inc. Pyridopyrimdinone CDK2/4/6 inhibitors
JP2020503289A (en) * 2016-12-14 2020-01-30 ターベダ セラピューティクス インコーポレイテッドＴａｒｖｅｄａ Ｔｈｅｒａｐｅｕｔｉｃｓ，Ｉｎｃ． HSP90 targeting conjugates and formulations thereof
WO2019157516A1 (en) 2018-02-12 2019-08-15 resTORbio, Inc. Combination therapies
LT3813946T (en) 2018-06-15 2024-07-10 Janssen Pharmaceutica Nv Rapamycin analogs and uses thereof
US20220220103A1 (en) * 2018-12-28 2022-07-14 Spv Therapeutics Inc. Cyclin-dependent kinase inhibitors
US20230048132A1 (en) * 2018-12-28 2023-02-16 Spv Therapeutics Inc. Cyclin-dependent kinase inhibitors
US11583538B2 (en) 2019-04-08 2023-02-21 Venenum Biodesign, LLC Substituted pyrrolo[1,2-a]pyrazines and pyrrolo[1,2-a][1,4]diazepines as TREX1 inhibitors
CN115209897A (en) 2019-12-05 2022-10-18 安纳库利亚治疗公司 Rapamycin analogs and uses thereof
CN114901664B (en) * 2020-01-10 2024-07-02 南京再明医药有限公司 Pyridone compounds and uses thereof
WO2022075974A1 (en) * 2020-10-06 2022-04-14 Venenum Biodesign, LLC Cyclic trex1 inhibitors
MX2023005747A (en) 2020-11-18 2023-07-28 Deciphera Pharmaceuticals Llc Gcn2 and perk kinase inhibitors and methods of use thereof.
EP4433061A4 (en) * 2021-11-18 2025-09-03 Onconova Therapeutics Inc METHODS AND COMPOSITIONS FOR THE TREATMENT OF CANCER
UY40772A (en) 2023-06-08 2024-12-31 Nimbus Wadjet Inc WRN INHIBITORS
WO2025137599A1 (en) * 2023-12-21 2025-06-26 Nimbus Wadjet, Inc. Wrn inhibitors

Family Cites Families (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5264437A (en) * 1992-03-20 1993-11-23 Syntex (U.S.A.) Inc. Optionally substituted pyrido[2,3-d]pyridine-2,4(1H,3H)-diones and pyrido[2,]pyrimidine-2(1H,3H)-ones
RU2191188C2 (en) 1994-11-14 2002-10-20 Варнер-Ламберт Компани Derivatives of 6-arylpyrido[2,3-d]pyrimidines and -naphthyridines, pharmaceutical composition showing inhibitory effect on cellular proliferation induced by protein tyrosine kinase and method of inhibition of cellular proliferation
CN1177960A (en) * 1995-03-10 1998-04-01 圣诺菲药品有限公司 6-Substituted pyrazolo[3,4-d]pyrimidin-4-ones, compositions and methods of use thereof
IL117923A (en) 1995-05-03 2000-06-01 Warner Lambert Co Anti-cancer pharmaceutical compositions containing polysubstituted pyrido¬2,3-d¾pyrimidine derivatives and certain such novel compounds
US5925761A (en) 1997-02-04 1999-07-20 Sepracor Inc. Synthesis of terfenadine and derivatives
ATE391719T1 (en) 1997-02-05 2008-04-15 Warner Lambert Co PYRIDO (2,3-D) PYRIMIDINES AND 4-AMINO-PRIMIDINES AS INHIBITORS OF CELLULAR PROLIFERATION
US6498163B1 (en) * 1997-02-05 2002-12-24 Warner-Lambert Company Pyrido[2,3-D]pyrimidines and 4-aminopyrimidines as inhibitors of cellular proliferation
GB9904932D0 (en) 1999-03-04 1999-04-28 Glaxo Group Ltd Composition and method for preventing/reducing the severity of side effects of chemotherapy and/or radiation therapy
SK10772002A3 (en) 2000-01-27 2004-01-08 Warner-Lambert Company Pyridopyrimidinone derivatives for treatment of neurodegenerative disease
HUP0300136A2 (en) 2000-03-06 2003-05-28 Warner Lambert Co 5-alkylpyrido [2,3-d]pyrimidines tyrosine kinase inhibitors, pharmaceutical compositions containing them and their use
EP1277738B1 (en) 2000-04-27 2011-03-30 Astellas Pharma Inc. Condensed heteroaryl derivatives
EP1364950A4 (en) 2001-02-26 2005-03-09 Tanabe Seiyaku Co PYRIDOPYRIMIDINE OR NAPHTHYRIDINE DERIVATIVE
US7019002B2 (en) * 2001-12-11 2006-03-28 Pharmacia & Upjohn, S.P.A. Pyridopyrimidinones derivatives as telomerase inhibitors
BR122016021801B8 (en) 2002-01-22 2021-05-25 Warner Lambert Co compounds 2-(pyridin-2-ylamino)-pyrido[2,3-d]pyrimidin-7-ones
JP2003321472A (en) 2002-02-26 2003-11-11 Takeda Chem Ind Ltd Grk inhibitor
RU2004133811A (en) 2002-04-19 2005-04-20 Смитклайн Бичам Корпорейшн (US) NEW COMPOUNDS
CN1653077A (en) 2002-05-06 2005-08-10 健亚生物科技公司 Nucleoside derivatives for treating hepatitis C virus infection
JP2004083587A (en) 2002-08-06 2004-03-18 Tanabe Seiyaku Co Ltd Pharmaceutical composition
US7098332B2 (en) * 2002-12-20 2006-08-29 Hoffmann-La Roche Inc. 5,8-Dihydro-6H-pyrido[2,3-d]pyrimidin-7-ones
JP2004203751A (en) 2002-12-24 2004-07-22 Pfizer Inc Substituted 6,6-heterobicyclic derivatives
WO2004063195A1 (en) 2003-01-03 2004-07-29 Sloan-Kettering Institute For Cancer Research Pyridopyrimidine kinase inhibitors
WO2004089930A1 (en) 2003-04-02 2004-10-21 Imclone Systems Incorporated 4-fluoroquinolone derivatives and their use as kinase inhibitors
WO2005040337A2 (en) 2003-05-20 2005-05-06 The Regents Of The University Of California METHODS FOR BINDING AGENTS TO β-AMYLOID PLAQUES
DK1648889T3 (en) 2003-07-11 2009-01-05 Warner Lambert Co Isethionate salt of a selective CDK4 inhibitor
NZ544697A (en) 2003-07-22 2009-03-31 Janssen Pharmaceutica Nv Quinolinone derivatives as inhibitors of c-fms kinase
US7160888B2 (en) * 2003-08-22 2007-01-09 Warner Lambert Company Llc [1,8]naphthyridin-2-ones and related compounds for the treatment of schizophrenia
WO2005080393A1 (en) 2004-02-14 2005-09-01 Irm Llc Compounds and compositions as protein kinase inhibitors
CA2555724A1 (en) * 2004-02-18 2005-09-09 Warner-Lambert Company Llc 2-(pyridin-3-ylamino)-pyrido[2,3-d]pyrimidin-7-ones
WO2005094830A1 (en) 2004-03-30 2005-10-13 Pfizer Products Inc. Combinations of signal transduction inhibitors
WO2005105097A2 (en) 2004-04-28 2005-11-10 Gpc Biotech Ag Pyridopyrimidines for treating inflammatory and other diseases
ES2292130T3 (en) * 2004-05-04 2008-03-01 Warner-Lambert Company Llc PIRIDO (2,3-D) PIRIMIDIN-7-PIRROLIL-SUBSTITUTED WAVES AND DERIVED FROM THEMSELVES AS THERAPEUTIC AGENTS.
WO2005117980A1 (en) 2004-06-04 2005-12-15 Pfizer Products Inc. Method for treating abnormal cell growth
WO2006021547A1 (en) 2004-08-26 2006-03-02 Boehringer Ingelheim International Gmbh Pteridinones used as plk (polo like kinase) inhibitors
EP1807440B1 (en) 2004-11-03 2020-02-19 The University of Kansas Novobiocin analogues as anticancer agents
CA2590294A1 (en) 2004-12-13 2006-06-22 Sunesis Pharmaceuticals, Inc. Pyrido pyrimidinones, dihydro pyrimido pyrimidinones and pteridinones useful as raf kinase inhibitors
US20060142312A1 (en) * 2004-12-23 2006-06-29 Pfizer Inc C6-aryl and heteroaryl substituted pyrido[2,3-D] pyrimidin-7-ones
JP5480503B2 (en) * 2005-10-07 2014-04-23 エクセリクシス， インク． PI3Kα pyridopyrimidinone type inhibitor
US8044062B2 (en) * 2005-10-07 2011-10-25 Exelixis, Inc. Substituted pyrido[2,3-d]pyrimidin-7(8H)-one inhibitors of phospatidylinositol 3-kinase alpha
EP1872922A1 (en) * 2006-06-27 2008-01-02 Nederlandse Organisatie voor Toegepast-Natuuurwetenschappelijk Onderzoek TNO Method and apparatus for manufacturing a polymeric article
CA2658725A1 (en) 2006-08-16 2008-02-21 Exelixis, Inc. Using pi3k and mek modulators in treatments of cancer
BRPI0716749B8 (en) * 2006-09-15 2021-05-25 Pfizer Prod Inc pyrido(2,3-d) pyrimidinone compounds, their use as pi3 inhibitors and pharmaceutical composition comprising them
GEP20135925B (en) * 2007-03-14 2013-10-10 Exelixis Patent Co Llc Inhibitors of hedgehog pathway
AU2008239596B2 (en) * 2007-04-11 2013-08-15 Exelixis, Inc. Pyrido [2,3-D] pyrimidin-7-one compounds as inhibitors of PI3K-alpha for the treatment of cancer
UY32153A (en) * 2008-09-30 2011-04-29 Exelixis Inc PY13KA (ALFA) AND MTOR PYRIDOMIDINONE INHIBITORS
AU2011239537A1 (en) * 2010-04-16 2012-11-15 Curis, Inc. Treatment of cancers having K-ras mutations

Also Published As

Publication number Publication date
CN101573358B (en) 2012-05-30
US8633204B2 (en) 2014-01-21
US8273755B2 (en) 2012-09-25
MA30709B1 (en) 2009-09-01
US20120309775A1 (en) 2012-12-06
HRP20110621T1 (en) 2011-09-30
PL2074122T3 (en) 2011-10-31
JP4718637B2 (en) 2011-07-06
JP2010503653A (en) 2010-02-04
NZ575167A (en) 2010-10-29
CU23783B7 (en) 2012-02-15
US7696213B2 (en) 2010-04-13
ES2366489T3 (en) 2011-10-20
UY30588A1 (en) 2008-05-02
HRP20110621T2 (en) 2013-12-06
WO2008032162A8 (en) 2009-03-26
MEP8009A (en) 2011-12-20
TN2009000085A1 (en) 2010-08-19
EP2074122B1 (en) 2011-06-29
ES2366489T9 (en) 2013-12-27
MX2009002927A (en) 2009-03-31
NO342357B1 (en) 2018-05-14
US20080090801A1 (en) 2008-04-17
CN101573358A (en) 2009-11-04
RS51927B (en) 2012-02-29
IL197243A (en) 2013-07-31
DOP2009000039A (en) 2015-12-15
NI200900032A (en) 2010-05-14
TW200820972A (en) 2008-05-16
GT200700077A (en) 2009-08-03
DK2074122T3 (en) 2011-08-15
IL197243A0 (en) 2009-12-24
CL2007002682A1 (en) 2008-04-04
AP2009004790A0 (en) 2009-04-30
AP2710A (en) 2013-07-30
KR101099926B1 (en) 2011-12-28
GEP20115306B (en) 2011-10-10
DK2074122T5 (en) 2014-03-17
EA200970207A1 (en) 2009-08-28
RS20090104A (en) 2010-06-30
US20100137279A1 (en) 2010-06-03
AU2007297212B2 (en) 2011-04-14
CR10662A (en) 2009-04-17
BRPI0716749A2 (en) 2014-02-18
EA016388B1 (en) 2012-04-30
AU2007297212A1 (en) 2008-03-20
CA2663401A1 (en) 2008-03-20
MY146420A (en) 2012-08-15
EP2074122A1 (en) 2009-07-01
PE20080670A1 (en) 2008-06-14
ZA200901477B (en) 2010-07-28
CA2663401C (en) 2011-07-12
BRPI0716749B1 (en) 2020-10-06
PT2074122E (en) 2011-08-24
BRPI0716749B8 (en) 2021-05-25
AU2007297212B8 (en) 2011-04-28
HK1138589A1 (en) 2010-08-27
CY1111911T1 (en) 2015-11-04
SI2074122T1 (en) 2011-10-28
ATE514695T1 (en) 2011-07-15
TWI334353B (en) 2010-12-11
KR20090040389A (en) 2009-04-23
EP2074122B9 (en) 2013-09-11
CU20090040A7 (en) 2011-07-11
AR062785A1 (en) 2008-12-03
WO2008032162A1 (en) 2008-03-20
HN2007000267A (en) 2011-02-25

Similar Documents

Publication Publication Date Title
NO20091141L (en) Pyrido (2,3-D) pyrimidinone compounds and their use as P13 inhibitors
NO20082090L (en) Pyridopyrimidinone inhibitors of P13K alpha
NO20073791L (en) Pyrazolylaminopyridine derivatives useful as kinase inhibitors
NO20063468L (en) Triazole compounds and their use as metabotrophic glutamate receptor antagonists
CO6321276A2 (en) TIAZOL DERIVATIVES USED AS PI3-CINASA INHIBITORS
NO20063470L (en) Tetrazole compounds and their use of metabotrophic glutamate receptor antagonists
NO20083427L (en) Cystotoxic agents comprising novel tomaymycin derivatives and their therapeutic use
PH12013501489A1 (en) Substituted 6,6-fused nitrogenous heterocyclic compounds and uses thereof
SMAP201100019A (en) Organic compounds.
WO2009016460A3 (en) Pyrazole compounds and their use as raf inhibitors
NO20075624L (en) Novel histamine H3 receptor ligands and their therapeutic uses
WO2007105058A8 (en) Pyrazole compounds
NO20063469L (en) Polyeheterocyclic compounds and their use as metabotrophic glutamate receptor antagonists
NO20083717L (en) Pyrrolotriazine-aniline prodrugs useful as kinase inhibitors
NO20075406L (en) Pyrimidine dione derivatives as prokineticin-2 receptor antagonists
NO20085107L (en) Spirocyclic nitriles as protease inhibitors
UA107784C2 (en) Inhibitor of melanin production
NO20083708L (en) 4-Phenyl-thiazole-5-carboxylic acid and 4-phenyl-thiazole-5-carboxylmides as PLK1 inhibitors
NO20063821L (en) Quinoline derivatives for use as mycobacterial inhibitors
EA200801608A1 (en) DERIVATIVES OF BENZIMIDAZOLONIC CARBONIC ACID
MX2012000177A (en) Substituted 2-carboxamide cycloamino ureas.
NO20060718L (en) Substituted thiophones and their use
NO20082589L (en) New indolizine derivatives, processes for preparing the same and therapeutic compositions which include the same
DK1819704T3 (en) Pyrrolopyridine-2-carboxylic acid amide derivative useful as an inhibitor of glycogen phosphorylase
UA95113C2 (en) Pyrido (2,3-d) pyrimidin0ne compounds and their use as pi3 inhibitors

Legal Events

Date Code Title Description
MM1K Lapsed by not paying the annual fees